CLVLY (CLVLY) Stock Price & Analysis
CLVLY (CLVLY) fell 2.15% to USD 6.36 as of June 10, 2026 at 02:27 UTC, according to Nexqual real-time market data.
CLVLY last closed at USD 6.5; the session ranged USD 6.36–6.5 on volume of 1,932 shares. Market capitalization is $331.74M, with a 52-week range of USD 5.98–9 (PNK). Source: Nexqual, June 10, 2026 at 02:27 UTC.
Key Statistics (as of June 10, 2026 at 02:27 UTC)
| Price | USD 6.36 |
|---|---|
| Change | ▼ 2.15% (down) |
| Previous Close | USD 6.5 |
| Open | USD 6.5 |
| Day Range | USD 6.36 – 6.5 |
| 52-Week Range | USD 5.98 – 9 |
| Volume | 1,932 shares |
| Market Cap | $331.74M |
| Exchange | PNK |
Technical Analysis (CLVLY)
Nexqual's technical model rates CLVLY "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.63 (neutral) |
| vs SMA50 | Below (USD 6.65) |
| MACD | -0.06 (negative) |
Analyst Ratings (CLVLY)
Wall Street analysts rate CLVLY "None", per Nexqual as of June 10, 2026 at 02:27 UTC.
| Consensus Rating | None |
|---|
Earnings (CLVLY)
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financials & Fundamentals (CLVLY)
| Total Revenue | $96.30M |
|---|---|
| Revenue Growth (YoY) | +3.60% |
| Gross Margin | +89.63% |
| Operating Margin | +36.59% |
| Profit Margin | +33.79% |
| ROE | +13.96% |
| Debt / Equity | 0.13 |
| Current Ratio | 14.64 |
| Total Cash | $233.00M |
| Total Debt | $323,843 |
| Free Cash Flow | $32.20M |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financial Health Score (CLVLY)
Nexqual rates CLVLY's overall financial health "Strong" across five dimensions, as of June 10, 2026 at 02:27 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 90%, operating 37% |
| Balance Sheet | Strong — $233M cash, no debt |
| Cash Flow | Strong — FCF $32M, 34% margin |
| Efficiency | Mixed — ROE 14%, ROA 10.6% |
Ownership (CLVLY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 50.43M |
| Float | 41.57M |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Leadership (CLVLY)
CLVLY is led by Philippe Jacques Wolgen (age 62), CEO, MD & Director, per Nexqual as of June 10, 2026 at 02:27 UTC.
| CEO, MD & Director | Philippe Jacques Wolgen (age 62) |
|---|---|
| Chief Financial Officer | Peter Vaughan |
| Chief Scientific Officer | Dennis J. Wright BPharm, M.Sc. |
| Director of North American Operations | Linda Teng |
| Director of Global Clinical Affairs | Emilie Rodenburger |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLVLF | Clinuvel Pharmaceuticals Ltd. | USD 6.4 | ▲ 0% |
| CUV.AX | CLINUVEL FPO [CUV] | AUD 8.72 | ▼ 4.49% |
| SPHRY | Starpharma Holdings Ltd. | USD 5.1 | ▼ 2.67% |
| CSLLY | CSL Ltd. | USD 17.44 | ▲ 1.87% |
| CMSQY | Computershare Ltd. | USD 25.11 | ▲ 2.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:27 UTC. This page is informational and not investment advice.